News
PVCT
0.054
0.00%
0.000
Weekly Report: what happened at PVCT last week (0831-0904)?
Weekly Report · 4d ago
Weekly Report: what happened at PVCT last week (0824-0828)?
Weekly Report · 08/31 10:07
Weekly Report: what happened at PVCT last week (0817-0821)?
Weekly Report · 08/24 10:08
Weekly Report: what happened at PVCT last week (0810-0814)?
Weekly Report · 08/17 10:09
Weekly Report: what happened at PVCT last week (0803-0807)?
Weekly Report · 08/10 10:04
Weekly Report: what happened at PVCT last week (0727-0731)?
Weekly Report · 08/03 10:04
Weekly Report: what happened at PVCT last week (0720-0724)?
Weekly Report · 07/27 10:08
Weekly Report: what happened at PVCT last week (0713-0717)?
Weekly Report · 07/20 10:05
Weekly Report: what happened at PVCT last week (0706-0710)?
Weekly Report · 07/13 10:06
Weekly Report: what happened at PVCT last week (0629-0703)?
Weekly Report · 07/06 10:09
Provectus Converts Directors’ Fees into Series D-1 Equity
TipRanks · 07/01 10:35
Provectus awarded patent for light-independent antibacterial eye drop
TipRanks · 06/30 13:10
Weekly Report: what happened at PVCT last week (0622-0626)?
Weekly Report · 06/29 10:05
Provectus Shareholders Approve Reverse Stock Split Authority
TipRanks · 06/22 14:01
Weekly Report: what happened at PVCT last week (0615-0619)?
Weekly Report · 06/22 10:13
Provectus Plans Broad Strategic Update at Annual Meeting
TipRanks · 06/18 19:27
Weekly Report: what happened at PVCT last week (0608-0612)?
Weekly Report · 06/15 10:14
Weekly Report: what happened at PVCT last week (0601-0605)?
Weekly Report · 06/08 10:10
Weekly Report: what happened at PVCT last week (0525-0529)?
Weekly Report · 06/01 10:14
Weekly Report: what happened at PVCT last week (0518-0522)?
Weekly Report · 05/25 10:17
More
Webull provides a variety of real-time PVCT stock news. You can receive the latest news about Provectus Biopha through multiple platforms. This information may help you make smarter investment decisions.
About PVCT
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.